Current approaches in treatment of triple-negative breast cancer.
Wahba HA, El-Hadaad HA. · 2015
Read Current approaches in treatment of triple-negative breast cancer. by Wahba HA, El-Hadaad HA. (2015) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4493381.txt.
Description
Hanan Ahmed Wahba and Hend Ahmed El-Hadaad reviewed treatment of triple-negative breast cancer in Cancer Biology and Medicine in 2015. These tumors lack estrogen and progesterone receptors and do not overproduce HER2, the three markers that guide most breast cancer therapy. Patients therefore cannot benefit from hormonal treatments or HER2-targeted drugs such as trastuzumab. The disease strikes younger and premenopausal women more often, and African American women especially.
Biologically aggressive, triple-negative cancers can still respond well to chemotherapy at first, in some reports better than other breast cancers. But the disease-free interval after treatment is short, and once spread, the course is rapid, so prognosis stays poor. The review covers current chemotherapy approaches and regimens in early and advanced settings, and the search for new targets in a cancer defined by the targets it lacks.
Catalog record
| CREATOR | Wahba HA, El-Hadaad HA. |
|---|---|
| YEAR | 2015 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 52 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |